Zacks Investment Research cut shares of Quotient (NASDAQ:QTNT) from a hold rating to a sell rating in a research note released on Friday.
According to Zacks, “Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania. “
Other analysts have also issued reports about the company. ValuEngine upgraded Quotient from a hold rating to a buy rating in a report on Thursday, October 18th. BidaskClub lowered Quotient from a buy rating to a hold rating in a report on Wednesday, July 18th.
Quotient (NASDAQ:QTNT) last issued its quarterly earnings results on Monday, November 5th. The company reported ($0.53) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.17). The company had revenue of $6.25 million during the quarter, compared to analyst estimates of $5.80 million. On average, research analysts anticipate that Quotient will post -1.92 EPS for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the business. Paloma Partners Management Co bought a new stake in shares of Quotient in the second quarter valued at $1,240,000. Citadel Advisors LLC bought a new stake in shares of Quotient in the second quarter valued at $902,000. Bellevue Group AG raised its stake in shares of Quotient by 190.7% in the second quarter. Bellevue Group AG now owns 319,814 shares of the company’s stock valued at $2,568,000 after buying an additional 209,814 shares during the period. Ardsley Advisory Partners raised its stake in shares of Quotient by 10.0% in the second quarter. Ardsley Advisory Partners now owns 110,000 shares of the company’s stock valued at $883,000 after buying an additional 10,000 shares during the period. Finally, Point72 Asset Management L.P. bought a new stake in shares of Quotient in the second quarter valued at $3,179,000. Hedge funds and other institutional investors own 49.19% of the company’s stock.
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Further Reading: Why is the ex-dividend date different from the record date?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.